News Sentiment

KZIA sentiment intelligence

Kazia Therapeutics Ltd ADR news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 46 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 13.56 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 38

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+2.3% over one week, -5.0% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

Kazia Therapeutics (KZIA) grants 100,000 ADS options to CMC director

Market Reaction

Balanced read

67/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 82/100 classification
One-week reaction 2.3% Price confirming higher
Trend fit Trend active -5.0% over four weeks
Fair value -15.6% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 28
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 38
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 14
Market source 7
TradingKey 7
Moomoo 6
TradingView 3
simplywall.st 2
Investing.com 1
Investing.com Canada 1

Event Lens

What the news is about

Classified themes
Market update 27
Earnings 11
Analyst action 7
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-46 of 46
Market source Direct company coverage

Kazia Therapeutics Appoints James Levine as Chief Financial Officer

Kazia Therapeutics has appointed James Levine as its Chief Financial Officer, effective June 1, 2026. Mr. Levine brings over two decades of experience in investment banking and financial leadership at publicly traded biotech companies, including roles at Cardiff Oncology and Cida

Tone
Positive 75/100
Event
Market update
Published
02 Jun 2026 23:11
Source
Market source
Stock Titan Direct company coverage

Kazia Therapeutics (NASDAQ: KZIA) registers 10.7M ADS; names new CFO

Kazia Therapeutics has filed a prospectus supplement to register 10,700,211 American Depositary Shares (ADSs), representing 5,350,105,500 ordinary shares. Concurrently, the company announced the appointment of James Levine as its Chief Financial Officer, effective June 1, 2026, w

Tone
Neutral 50/100
Event
Market update
Published
02 Jun 2026 15:08
Source
Stock Titan
www.marketscreener.com Direct company coverage

Kazia Therapeutics Limited Announces Appointment of James Levine to Chief Financial Officer, Effective June 1, 2026

Kazia Therapeutics Limited has announced the appointment of James Levine as its Chief Financial Officer, effective June 1, 2026. Levine brings over two decades of experience in investment banking and financial leadership at publicly traded biotech companies, including roles at Ca

Tone
Positive 72/100
Event
Market update
Published
02 Jun 2026 14:39
Source
www.marketscreener.com
Stock Titan Direct company coverage

Kazia Therapeutics (NASDAQ: KZIA) appoints James Levine as new CFO

Kazia Therapeutics Limited announced the appointment of James Levine as its new Chief Financial Officer, effective June 1, 2026. Mr. Levine's compensation package includes an annual base salary of US$475,000, a target bonus of 40% of base salary, and options for 200,000 American

Tone
Neutral 50/100
Event
Analyst action
Published
02 Jun 2026 13:09
Source
Stock Titan